Home » Stocks » APTX

Aptinyx Inc. (APTX)

Stock Price: $2.39 USD -0.07 (-2.85%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $2.38 -0.01 (-0.42%) May 13, 6:23 PM
Market Cap 160.06M
Revenue (ttm) 1.56M
Net Income (ttm) -50.05M
Shares Out 66.97M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.39
Previous Close $2.46
Change ($) -0.07
Change (%) -2.85%
Day's Open 2.47
Day's Range 2.34 - 2.47
Day's Volume 381,103
52-Week Range 2.30 - 6.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 days ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 weeks ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 weeks ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 weeks ago - Business Wire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: BLRX, CYCN, LCTX, PTN
2 weeks ago - PennyStocks

Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and deme...

1 month ago - Benzinga

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 51.22% year over year to ($0.20), which beat the estima...

1 month ago - Benzinga

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brai...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiat...

6 months ago - Benzinga

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: SELB, VBIV
6 months ago - The Motley Fool

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Investors reacted negatively to the company's announcement of a secondary stock offering.

6 months ago - The Motley Fool

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today appeared fi...

6 months ago - InvestorPlace

The biotech's PTSD drug hit the mark in a midstage trial.

6 months ago - The Motley Fool

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

6 months ago - Zacks Investment Research

Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Ph...

6 months ago - Market Watch

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

7 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

8 months ago - Business Wire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CBAY, EOLS, IBIO, SIEN
8 months ago - 24/7 Wall Street

Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

9 months ago - Business Wire

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

9 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

9 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

10 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will...

10 months ago - Business Wire

Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma

10 months ago - Seeking Alpha

Data readout expected by late 2020 Data readout expected by late 2020

10 months ago - GlobeNewsWire

Is (APTX) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Aptinyx.

11 months ago - Zacks Investment Research

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
Stock Exchange
NASDAQ
Ticker Symbol
APTX
Full Company Profile

Financial Performance

In 2020, Aptinyx's revenue was $1.56 million, a decrease of -57.37% compared to the previous year's $3.67 million. Losses were -$50.05 million, -12.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Aptinyx stock is "Buy." The 12-month stock price forecast is 10.57, which is an increase of 342.26% from the latest price.

Price Target
$10.57
(342.26% upside)
Analyst Consensus: Buy